Suspension of trading

News Acorda Therapeutics OTC Markets

Stocks

ACOR

US00484M7002

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-10.00%	-99.91%

13/08/24	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.	CI
07/08/24	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.	CI

All News

Mentions Relevance

06/08/25	Federal Circuit Denies Appellate Jurisdiction Based On Alternative Ground For Relief	AQ
13/08/24	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.	CI
09/08/24	Acorda Therapeutics : UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Form 8 K	PU
07/08/24	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.	CI
30/07/24	First Motion for Exclusivity Period Extension Filed by Acorda Therapeutics, Inc.	CI
11/07/24	Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics	AQ
10/07/24	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
03/07/24	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	CI
01/07/24	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
12/06/24	Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	CI
14/05/24	Acorda: Q1 Earnings Snapshot	AQ
14/05/24	Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/05/24	Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
03/05/24	Final DIP Financing Approved for Acorda Therapeutics, Inc.	CI
29/04/24	Bidding Procedure Approved for Acorda Therapeutics, Inc.	CI
16/04/24	Acorda Therapeutics Announces Delisting from Nasdaq	BU
05/04/24	Interim DIP Financing Approved for Acorda Therapeutics, Inc.	CI
05/04/24	Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index	CI
01/04/24	Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
08/08/23	Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023